30 closest matches · ranked by relevance
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients
Hepatic Cancer
Primary: Treatment Response — 16; 14; 4 Participants
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
Hepatocellular Carinoma
Primary: Number of Participants With Radiographic Response — 4 Participants
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
Liver Cancer · Pancreatic Cancer
Primary: Median Overall Survival (OS) — 14.09 months
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Stage III Distal Bile Duct Cancer AJCC v8 · Stage III Gallbladder Cancer AJCC v8 · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Overall Survival (OS) — 14.0; 13.6 months — p=0.41
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Breast Cancer · Stage IV Breast Cancer
Primary: 3-year Overall Survival Rate — 67.9; 68.4 percentage of participants — p=0.32
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Advanced Hepatocellular Carcinoma · BCLC Stage A Hepatocellular Carcinoma · BCLC Stage B Hepatocellular Carcinoma
Primary: Progression-free Survival (PFS) — 23.1 percentage of participants
Colorectal Cancer · Liver Neoplasms
Primary: Incidence of Adverse Events and Dose Limiting Adverse Events — 0; 69; 47; 44 percentage of participants
Hepatocellular Carcinoma · Liver Cancer
Primary: Tumor Response — 0; 7; 47; 11 Participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Cancer
Primary: Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib — 23.6; 30.7; 30.5; 20.5 micromolar
Hepatocellular Carcinoma
Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536
Carcinoma, Hepatocellular
Primary: Tumour Stabilisation Rate — 5.3; 16.0; 8.7 percentage of patients
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Hepatocellular Carcinoma
Primary: Number of Adverse Events — 12; 2; 8; 4 events
Carcinoma, Hepatocellular
Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants
Hepatocellular Carcinoma
Primary: Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB — 0; 0; 0; 0 Dose limiting toxicities